Evaluation of two doses of etoricoxib, a COX-2 selective non-steroidal anti-inflammatory drug (NSAID), in the treatment of Rheumatoid Arthritis in a double-blind, randomized controlled trial
Crossref DOI link: https://doi.org/10.1186/s12891-016-1170-0
Published Online: 2016-08-08
Published Print: 2016-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Bickham, Kara
Kivitz, Alan J.
Mehta, Anish
Frontera, Nancy
Shah, Sandhya
Stryszak, Paul
Popmihajlov, Zoran
Peloso, Paul M.
Funding for this research was provided by:
Merck
License valid from 2016-08-08